Akums Drugs Adjusts Evaluation Amidst Strong Financial Performance and Market Trends
Akums Drugs & Pharmaceuticals has recently adjusted its evaluation, reflecting changes in financial metrics and market position. The company reported strong Q4 FY24-25 results, with significant net sales and profit growth. Despite modest annual growth rates, the stock's technical indicators have shifted, indicating a complex market performance landscape.
Akums Drugs & Pharmaceuticals has recently undergone an evaluation adjustment, reflecting changes in its underlying financial metrics and market position. The stock's technical indicators have shifted, with the technical trend moving from a mildly bearish stance to a sideways position. This adjustment highlights a nuanced view of the stock's performance in the current market environment.In terms of financial performance, Akums Drugs reported a notable quarter in Q4 FY24-25, achieving net sales of Rs 1,055.55 crore and a profit after tax of Rs 139.40 crore, marking significant growth. The earnings per share reached Rs 9.64, contributing to a return on equity of 10.6%. Despite these positive results, the company has experienced a modest annual growth rate in net sales of 6.10% and an operating profit growth of 17.54% over the past five years.
The stock's current price stands at Rs 585.50, with a 52-week high of Rs 1,174.85 and a low of Rs 407.40. The company's low debt-to-equity ratio further supports its financial stability. Overall, the recent evaluation adjustment reflects a complex interplay of technical trends and financial performance indicators for Akums Drugs & Pharmaceuticals.
Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
